to the soluble form of IL-6R. Th e IL-6/soluble IL-6R complex activates gp130, which is expressed on most cells, including neurons. While the functional role of gp130 expressed on neurons is not well understood, this protein has been linked to sensitization of pain-sensing nerves through activation of phosphoinositide 3-kinase, protein kinase C-delta and Janus kinase/signal transducer and activator of transcription 3 signaling pathways and through regulation of the pain-activated ion channel TRPV1 [2, 3] . Using soluble glycoprotein 130 (sgp130), which binds and inactivates IL-6, Boettger and colleagues made several important fi ndings utilizing a rat model of antigen-induced arthritis.
First, the authors report that intraarticular administration of sgp130 attenuates arthritis-induced pain. Th is is an important fi nding as it suggests that IL-6 is a pain mediator -not only following nerve injury and tumor growth as has been reported earlier [2, 3] , but also subsequent to infl ammatory arthritis. Th e pain-relieving (antinociceptive) eff ect of local versus systemic injections of sgp130 was investigated, and, surprisingly, intraarticular injection of gp130 to the knee joint had a greater antinociceptive eff ect than intraperitoneal injections. Th is may be interpreted as local IL-6 in the joint being crucial for the nociceptive response, while circulating IL-6 is not. In such a case, one would expect a higher dose of systemic spg130 than used in Boettger and colleagues' study to have similar pain-relieving eff ects, given that it reaches the joint in high enough concentrations.
From a clinical perspective it is critical that a painrelieving drug has the ability to reverse alreadyestablished hypersensitivity, particularly in conditions such as arthritis where pain often is what brings the patient to seek medical attention. In the work presented by Boettger and colleagues, intraperitoneal post-treatment only decreased stimulus-evoked pain responses while intraarticular pretreatment had a broad antinociceptive eff ect, also normalizing weight bearing, locomotion and gait -measures thought to indirectly refl ect ongoing pain. Because the routes of administration were diff erent in the pretreatment versus post-treatment comparison (intra articular versus intraperitoneal, respectively), further studies are warranted to determine Abstract Pain management in conditions of chronic infl ammation is a clinical challenge, and increasing our understanding of the mechanisms driving this type of pain is important. In the previous issue of Arthritis Research & Therapy, Boettger and colleagues examine the role of IL-6 in antigen-induced arthritis using the IL-6 neutralizing soluble glycoprotein 130 and link IL-6 to a pathophysiological role in the generation of pain, independent of the proinfl ammatory properties of IL-6. The fi ndings presented in this study add to a growing body of evidence highlighting the role of IL-6 in the induction and maintenance of pain.
whether IL-6 inhibition is antinociceptive when administrated during active arthritis. Th is determination is particularly important from the aspect of the antigeninduced arthritis model being predictive of the human condition, as clinical studies have shown that rheumatoid arthritis patients treated with mono clonal IL-6R antibody score lower on the pain visual analog scale and report a reduced number of tender joints [4] .
Another noteworthy fi nding is that while one injection of sgp130 into the joint had an antinociceptive eff ect that lasted several days, no concurrent reduction of the joint infl ammation was observed. Blocking IL-6-mediated signaling, even in the presence of other factors that continuously drive the infl ammatory process, is therefore suffi cient to bring the nociceptive thresholds back towards normal levels. In support of this notion, it has been demonstrated that IL-6 can trigger activation of pain fi bers in the absence of infl ammation. Exposure to IL-6 sensitizes both peripheral and spinal sensory neurons by electrophysiological measures [5] [6] [7] , and applica tion of IL-6 to the peripheral nerve or into the cerebrospinal fl uid evokes long-lasting pain behavior [7, 8] , indicating that the IL6/soluble IL-6R complex may be acting directly on neurons. Th is does not exclude, however, the fact that IL-6 is also involved in the regulation of pain processing through actions on nonneuronal cells. For example, IL-6 is elevated in the spinal cord subsequent to peripheral nerve injury in rats, which has been linked to microglia activation and associated neuropathic pain [3, 8] .
Finally, Boettger and colleagues found that although sgp130 failed to attenuate joint infl ammation, bone erosion was reduced in the antigen-induced arthritis model. Th e structure-sparing eff ect of sgp130 is in line with recent work showing that IL-6R inhibition blocks osteoclast formation in vitro and in vivo, independent of the anti-infl ammatory eff ect [9] , and that bone erosion is reduced in rheumatoid arthritis patients on IL-6 inhibitor monotherapy [10] . Th e antinociceptive eff ect observed in the study by Boettger and colleagues was therefore possibly at least partly related to a prevention of joint destruction. Th is observation highlights the need for gaining a better and more detailed understanding of how bone erosion aff ects the sensory system. In summary, there are several potential sites and mechanisms through which IL-6 may drive pain in conditions such as rheumatoid arthritis. While there are still critical steps to take before adding IL-6 blockers to the list of painkillers, it is an intriguing thought that anticytokine therapies have the potential to become new tools for treatment of chronic pain.
